Clobetasol propionate 0.05%; crm ... Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used ...

Three cosmetic products have been withdrawn from the market after it was deemed they all had "serious chemical risks." Makari ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Taiwan-based Formosa Pharmaceuticals (6838: TW) revealed that it has entered into an exclusive licensing agreement with Medvisis Switzerland, in Switzerland and Liechtenstein, for exclusive rights to ...

EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an ...

Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic ...

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...

Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this ...